<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334203</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-259-0108</org_study_id>
    <nct_id>NCT01334203</nct_id>
  </id_info>
  <brief_title>A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of ranolazine compared to placebo on duration of&#xD;
      exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma&#xD;
      concentration after 12 weeks of treatment in subjects with chronic stable angina and coronary&#xD;
      artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy of ranolazine compared to placebo on duration of&#xD;
      exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma&#xD;
      concentration after 12 weeks of treatment in subjects with chronic stable angina and coronary&#xD;
      artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM). This is a&#xD;
      randomized, double-blind, placebo-controlled, parallel group study in subjects with chronic&#xD;
      stable angina and CAD receiving a stable dose of a single concomitant antianginal medication&#xD;
      who also have a history of T2DM; allowed antianginals will be a beta-blocker (atenolol or&#xD;
      metoprolol) or a calcium-channel blocker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of angina during peak ETT at week 12 or last visit</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 1 mm ST-segment depression during peak ETT at week 12 or last visit</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in exercise treadmill duration in the trough ETT at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.&#xD;
Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Males and females aged 18 to 79 years&#xD;
&#xD;
          -  Able to perform a Sheffield Modified Bruce Treadmill Exercise Protocol&#xD;
&#xD;
          -  At least a 3-months history of chronic stable angina triggered by physical effort and&#xD;
             relieved by rest and/or sublingual nitroglycerin&#xD;
&#xD;
          -  Coronary artery disease documented by one or more of the following:&#xD;
&#xD;
               -  Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries&#xD;
&#xD;
               -  History of myocardial infarction (MI) documented by positive CK-MB enzymes,&#xD;
                  troponins, or ECG changes&#xD;
&#xD;
               -  Cardiac nuclear scan studies diagnostic of CAD, e.g., thallium scan or ECHO with&#xD;
                  stress or pharmacologic interventions (adenosine, dipyridamole, etc.)&#xD;
&#xD;
          -  Stable treatment with one of the following antianginal medications for at least 4&#xD;
             weeks prior to Screening:&#xD;
&#xD;
               -  beta-blocker (atenolol up to 50 mg daily or metoprolol up to 100 mg daily)&#xD;
&#xD;
               -  dihydropyridine calcium-channel blocker (amlodipine up to 5 mg daily or&#xD;
                  nifedipine up to 30 mg daily)&#xD;
&#xD;
               -  non-dihydropyridine calcium-channel blocker (diltiazem 180 to 360 mg daily or&#xD;
                  verapamil 180 to 360 mg daily)&#xD;
&#xD;
          -  Willingness to discontinue other antianginals and be treated with one of the allowed&#xD;
             antianginal therapies&#xD;
&#xD;
          -  Documented history of type 2 diabetes mellitus&#xD;
&#xD;
          -  Females of childbearing potential must agree to utilize highly effective contraception&#xD;
             methods from Screening throughout the duration of study treatment and for 14 days&#xD;
             following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to exercise or having exercise limitation due to other co-morbidities that&#xD;
             may interfere with ability to perform required ETT (e.g., morbid obesity, significant&#xD;
             chronic lung disease, prior hospitalization for acute exacerbation of chronic lung&#xD;
             disease or home oxygen use, chronic oral steroid therapy that can limit exercise&#xD;
             capacity, osteoarthritis, peripheral artery disease, etc.)&#xD;
&#xD;
          -  Any absolute contraindication to ETT&#xD;
&#xD;
          -  Presence of electrocardiographic or other abnormalities that interfere with ECG&#xD;
             interpretation or may cause a false positive stress test (e.g., ≥ 1 mm horizontal or&#xD;
             down-sloping ST segment depression at rest in any standard ECG lead,&#xD;
             Lown-Ganong-Levine syndrome, Wolff-Parkinson-White syndrome, left bundle branch block,&#xD;
             left ventricular hypertrophy with repolarization abnormality, ventricular pacemaker,&#xD;
             etc.)&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  Clinically significant valvular heart disease or congenital cardiac defects&#xD;
&#xD;
          -  Acute coronary syndrome in the prior 2 months or coronary revascularization within the&#xD;
             prior 6 months or planned coronary revascularization during the study period&#xD;
&#xD;
          -  Stroke or transient ischemic attack within 6 months prior to Screening&#xD;
&#xD;
          -  History of serious ventricular dysrhythmias or a history of life-threatening&#xD;
             ventricular arrhythmia&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  QTc &gt; 0.5 seconds&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Uncontrolled hypertension (seated systolic blood pressure &gt; 180 mm Hg or diastolic&#xD;
             blood pressure &gt; 110 mm Hg)&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mm Hg&#xD;
&#xD;
          -  Inability to discontinue current antianginal medications and remain on one allowed&#xD;
             antianginal therapy&#xD;
&#xD;
          -  Clinically significant hepatic impairment&#xD;
&#xD;
          -  Creatinine clearance (CLCr) &lt; 30 ml/min&#xD;
&#xD;
          -  Prior treatment with ranolazine&#xD;
&#xD;
          -  Participation in another investigational drug or device study within 1 month prior to&#xD;
             Screening&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Positive serum pregnancy test&#xD;
&#xD;
          -  Current treatment with potent inhibitors of CYP3A (e.g., ketoconazole, itraconazole,&#xD;
             clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)&#xD;
&#xD;
          -  Current treatment with CYP3A and P glycoprotein (Pgp) inducers (e.g.,&#xD;
             rifampicin/rifampin, carbamazepine, St. John's wort)&#xD;
&#xD;
          -  History of illicit drug use or alcohol abuse within one year of screening&#xD;
&#xD;
          -  Any other conditions that, in the opinion of the investigator, are likely to prevent&#xD;
             compliance with the study protocol or pose a safety concern if the subject&#xD;
             participates in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Garg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jay Garg, MD, Director, Clinical Research</name_title>
    <organization>Gilead Sciences, Inc.</organization>
  </responsible_party>
  <keyword>Chronic angina</keyword>
  <keyword>Angina pectoris</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>ETT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

